Trial Profile
Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms B-R-ENDA; BRENDA
- 06 Nov 2019 Primary endpoint (2-year-progression-free survival (PFS) for efficacy (expected at 30-50% in the 80 yr cohort)) has been met as per Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology
- 12 Oct 2018 Status changed from recruiting to completed.